WCLC 2025 - Posters & ePosters-EP.12.29 Association Between Tepotinib-Induced Edema and Clinical Outcomes in Patients With MET Exon 14 Skipping NSCLC

EP.12.29 Association Between Tepotinib-Induced Edema and Clinical Outcomes in Patients With MET Exon 14 Skipping NSCLC

Pdf Summary

This retrospective multicenter study investigated the relationship between tepotinib-induced edema and clinical outcomes in Japanese patients with MET exon 14 skipping non-small cell lung cancer (NSCLC) receiving first-line tepotinib therapy. Data from 62 patients treated across six Japanese hospitals between August 2020 and December 2024 were analyzed. Edema was a common adverse event, occurring in 71% of patients (44/62), ranging from grade 1 to grade 3.<br /><br />Key findings showed that patients who developed edema had significantly higher objective response rates (ORR: 70.4% vs. 30.7%) and disease control rates (DCR: 93.1% vs. 76.9%) compared to those without edema. Progression-free survival (PFS) and overall survival (OS) were also markedly longer in the edema group, with median PFS of 10.8 months versus 4.2 months and median OS of 21.3 months versus 9.6 months. A 2-month landmark analysis confirmed these survival benefits remained significant for PFS.<br /><br />Edema led to treatment modifications in many patients: 37.1% underwent dose reductions, 25.8% had dose interruptions, and 8.1% discontinued tepotinib due to edema. Hypoalbuminemia and increased blood creatinine were also frequently observed adverse events associated with edema. Despite these modifications, discontinuation rates were low, consistent with prior studies such as the VISION trial.<br /><br />The study concluded that tepotinib-induced edema correlates with enhanced treatment efficacy, suggesting edema may be a clinical marker of drug activity. These findings highlight the importance of proactive management of edema and appropriate dose adjustments to optimize therapy outcomes in MET exon 14 skipping NSCLC patients receiving tepotinib. This real-world evidence supports the clinical utility of tepotinib and guides therapeutic decisions regarding adverse event management.

Asset Subtitle

Takayuki Kobayashi

Meta Tag

Speaker Takayuki Kobayashi

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

tepotinib

edema

MET exon 14 skipping

non-small cell lung cancer

NSCLC

first-line therapy

objective response rate

progression-free survival

overall survival

dose modification